Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Recruiting 1

Sponsor Class

OTHER_GOV 1

Study Type

Interventional 1

Sponsor

Cancer Type

Breast 1

Conditions

Breast Neoplasms 1Breast Diseases 1

Interventions

Specimen Handling 198Magnetic Resonance Spectroscopy 160pembrolizumab 141Carboplatin 117Biopsy 111Cyclophosphamide 93Cisplatin 93Paclitaxel 75Bevacizumab 61Gemcitabine 60Nivolumab 57fludarabine 53Radiotherapy 50Fluorouracil 49Pemetrexed 46Oxaliplatin 43Dexamethasone 43venetoclax 42Rituximab 41Leucovorin 41Doxorubicin 41durvalumab 40Docetaxel 40Capecitabine 39Radiation 37atezolizumab 35Prednisone 32Injections 31Fulvestrant 31Standard of Care 29

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Recruiting × dalpiciclib × 30 days × Clear all
NCT07581834 2026-05-12

Efficacy and Safety of Dalpiciclib Combined With Endocrine Adjuvant Therapy for Early HR +/HER2- Breast Cancer: a Multicenter, Prospective Clinical Study

Fujian Cancer Hospital

Phase 2 Recruiting
2,000 enrolled
Breast

Breast Diseases, Breast Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡